Choroid Plexus CarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Choroid Plexus Carcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Southeastern Retina Associates
Claxton Baer is an Ophthalmologist practicing medicine in Kingsport, Tennessee. Dr. Baer is rated as a Distinguished provider by MediFind in the treatment of Choroid Plexus Carcinoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Retinal Artery Occlusion. Dr. Baer is board certified in American Board Of Ophthalmology.
ETSU Physicians & Associates- Ophthalmology
Anne Eberhart is an Ophthalmologist practicing medicine in Johnson City, Tennessee. Dr. Eberhart is rated as an Advanced provider by MediFind in the treatment of Choroid Plexus Carcinoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Cataract, Coloboma of Optic Papilla, Coloboma of Optic Nerve, and Choroid Plexus Carcinoma. Dr. Eberhart is board certified in American Board Of Ophthalmology.
Bassett Medical Center
Sherif Khedr is an Ophthalmologist practicing medicine in Cooperstown, New York. Dr. Khedr is rated as an Advanced provider by MediFind in the treatment of Choroid Plexus Carcinoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Retinal Artery Occlusion.
Summary: The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) ne...
Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...